1. Home
  2. TNGX vs DCOMP Comparison

TNGX vs DCOMP Comparison

Compare TNGX & DCOMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tango Therapeutics Inc.

TNGX

Tango Therapeutics Inc.

HOLD

Current Price

$9.13

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo Dime Community Bancshares Inc. Fixed-Rate Non-Cumulative Perpetual Preferred Stock Series A

DCOMP

Dime Community Bancshares Inc. Fixed-Rate Non-Cumulative Perpetual Preferred Stock Series A

HOLD

Current Price

$18.14

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNGX
DCOMP
Founded
2014
N/A
Country
United States
United States
Employees
N/A
887
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TNGX
DCOMP
Price
$9.13
$18.14
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$12.50
N/A
AVG Volume (30 Days)
2.7M
N/A
Earning Date
11-04-2025
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$66,501,000.00
N/A
Revenue This Year
$53.01
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
53.29
N/A
52 Week Low
$1.03
N/A
52 Week High
$11.20
N/A

Technical Indicators

Market Signals
Indicator
TNGX
DCOMP
Relative Strength Index (RSI) 49.09 28.79
Support Level $8.89 $18.08
Resistance Level $10.22 $19.01
Average True Range (ATR) 0.62 0.28
MACD -0.15 -0.07
Stochastic Oscillator 10.83 10.81

Price Performance

Historical Comparison
TNGX
DCOMP

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About DCOMP Dime Community Bancshares Inc. Fixed-Rate Non-Cumulative Perpetual Preferred Stock Series A

Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.

Share on Social Networks: